Literature DB >> 19948880

Renoprotective effect of rosuvastatin in DOCA-salt hypertensive rats.

Eun Hui Bae1, In Jin Kim, Jeong Woo Park, Seong Kwon Ma, Jong Un Lee, Soo Wan Kim.   

Abstract

BACKGROUND: Pleiotropic effects of statins represent potential mechanisms for the treatment of end organ damage in hypertension. This study has investigated the effects of rosuvastatin (10 mg/kg/day) on renal function impairment, glomerulosclerosis and tubulointerstitial fibrosis in deoxycorticosterone acetate (DOCA)-salt hypertensive (DSH) rat.
METHODS: Rats were implanted with DOCA strips (200 mg/kg) on 1 week after unilateral nephrectomy. Rats received a controlled diet with or without rosuvastatin. Three weeks after DOCA implantation, systolic blood pressure (SBP) was measured by tail-cuff method. The glomerulosclerosis and tubulointerstitial fibrosis was determined by Masson's trichrome stain. The tumour necrosis factor (TNF-alpha), interleukin-1beta (IL-1beta), interferon-gamma (IFN-gamma), monocyte chemoattractant protein1 (MCP1), intercellular adhesion molecule-1 (ICAM-1) and endothelin-1 (ET-1) were determined by real-time polymerase chain reaction. The expression of ED-1, transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) was determined in the kidney by immunoblotting and immunohistochemistry.
RESULTS: In DSH rats, SBP was increased, which was not affected by rosuvastatin treatment. Creatinine clearance was decreased while urinary albumin excretion ratio was increased in DSH rats compared with controls, which were attenuated by rosuvastatin treatment. Glomerulosclerosis and tubulointerstitial fibrosis in DSH rats were attenuated by rosuvastatin treatment. The messenger RNA expression of TNF-alpha, IL-1beta, IFN-gamma, MCP1, ICAM-1 and ET-1 was increased in DSH, which was attenuated by rosuvastatin treatment. The expression of ED-1, TGF-beta and CTGF was increased in the kidney of DSH, which was counteracted by rosuvastatin treatment.
CONCLUSION: Rosuvastatin is effective in preventing progression of renal injury in DSH, the mechanism of which is associated with anti-inflammatory and anti-fibrotic effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19948880     DOI: 10.1093/ndt/gfp604

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

Review 1.  Dysregulation of T cell subsets in the pathogenesis of hypertension.

Authors:  Songcang Chen; Devendra K Agrawal
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

2.  Rosuvastatin beneficially alters the glomerular structure of kidneys from spontaneously hypertensive rats (SHRs).

Authors:  Erica Peres de Barros; Angélica Beatriz Garcia-Pinto; Priscilla Yório Machado; Mário José dos Santos Pereira; Jorge José de Carvalho
Journal:  J Mol Histol       Date:  2011-06-14       Impact factor: 2.611

Review 3.  Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Authors:  Michael S Kostapanos; Christos V Rizos; Moses S Elisaf
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

4.  Spontaneous one-kidney rats are more susceptible to develop hypertension by DOCA-NaCl and subsequent kidney injury compared with uninephrectomized rats.

Authors:  Xuexiang Wang; Ashley C Johnson; Jennifer M Sasser; Jan M Williams; Leah C Solberg Woods; Michael R Garrett
Journal:  Am J Physiol Renal Physiol       Date:  2016-03-02

5.  Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide-deficient rats.

Authors:  Jose Marcos Girardi; Rogerio Estevan Farias; Ana Paula Ferreira; Nadia Rezende Barbosa Raposo
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

6.  Dietary supplementation with essential amino acids boosts the beneficial effects of rosuvastatin on mouse kidney.

Authors:  Giovanni Corsetti; Giuseppe D'Antona; Chiara Ruocco; Alessandra Stacchiotti; Claudia Romano; Laura Tedesco; Francesco Dioguardi; Rita Rezzani; Enzo Nisoli
Journal:  Amino Acids       Date:  2014-06-13       Impact factor: 3.520

7.  Rosuvastatin attenuates contrast-induced nephropathy through modulation of nitric oxide, inflammatory responses, oxidative stress and apoptosis in diabetic male rats.

Authors:  Jie Deng; Guijun Wu; Chen Yang; Yi Li; Quanmin Jing; Yaling Han
Journal:  J Transl Med       Date:  2015-02-12       Impact factor: 5.531

8.  Renoprotective Effect of the Histone Deacetylase Inhibitor CG200745 in DOCA-Salt Hypertensive Rats.

Authors:  Eun Hui Bae; In Jin Kim; Ji Hong Song; Hong Sang Choi; Chang Seong Kim; Gwang Hyeon Eom; Inkyeom Kim; Hyunju Cha; Joong Myung Cho; Seong Kwon Ma; Soo Wan Kim
Journal:  Int J Mol Sci       Date:  2019-01-25       Impact factor: 5.923

9.  Adipose Mesenchymal Cells-Derived EVs Alleviate DOCA-Salt-Induced Hypertension by Promoting Cardio-Renal Protection.

Authors:  Rafael Soares Lindoso; Jarlene Alécia Lopes; Renata Binato; Eliana Abdelhay; Christina Maeda Takiya; Kildare Rocha de Miranda; Lucienne Silva Lara; Antonella Viola; Benedetta Bussolati; Adalberto Vieyra; Federica Collino
Journal:  Mol Ther Methods Clin Dev       Date:  2019-11-15       Impact factor: 6.698

10.  Activation of the Renal PI3K/Akt/mTOR Signaling Pathway in a DOCA-Salt Model of Hypertension.

Authors:  Seong Kwon Ma; Joon Seok Choi; Soo Yeon Joo; Ha Yeon Kim; Chang Seong Kim; Eun Hui Bae; Jong Un Lee; Soo Wan Kim
Journal:  Chonnam Med J       Date:  2012-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.